Shares of Gyre Therapeutics, Inc. (NASDAQ:GYRE – Get Free Report) saw unusually-high trading volume on Friday . Approximately 38,827 shares changed hands during trading, a decline of 47% from the previous session’s volume of 73,103 shares.The stock last traded at $9.96 and had previously closed at $9.78.
Gyre Therapeutics Stock Down 0.8 %
The company has a 50 day moving average of $13.14 and a two-hundred day moving average of $12.59.
Institutional Trading of Gyre Therapeutics
A number of hedge funds and other institutional investors have recently modified their holdings of the business. Barclays PLC boosted its stake in Gyre Therapeutics by 281.8% during the third quarter. Barclays PLC now owns 9,288 shares of the company’s stock worth $116,000 after acquiring an additional 6,855 shares in the last quarter. Geode Capital Management LLC boosted its position in shares of Gyre Therapeutics by 16.9% in the 3rd quarter. Geode Capital Management LLC now owns 303,647 shares of the company’s stock worth $3,808,000 after purchasing an additional 43,840 shares in the last quarter. State Street Corp grew its stake in shares of Gyre Therapeutics by 8.8% in the 3rd quarter. State Street Corp now owns 104,490 shares of the company’s stock worth $1,310,000 after buying an additional 8,412 shares during the last quarter. FMR LLC bought a new position in Gyre Therapeutics during the 3rd quarter valued at approximately $47,000. Finally, Advantage Alpha Capital Partners LP purchased a new position in Gyre Therapeutics during the third quarter valued at $334,000. 23.99% of the stock is owned by hedge funds and other institutional investors.
Gyre Therapeutics Company Profile
Gyre Therapeutics, Inc, a biopharmaceutical company, primarily focuses on the development and commercialization of Hydronidone for the treatment of Metabolic Dysfunction Associated Steatohepatitis in the United States. Its Hydronidone is also being evaluated for the treatment of liver fibrosis across a spectrum of chronic liver diseases.
Further Reading
- Five stocks we like better than Gyre Therapeutics
- How to Invest in the FAANG Stocks
- SoundHound AI: Can Its Meteoric Rise Sustain Into 2025?
- How Can Retail Investors Trade the Toronto Stock Exchange (TSX)?
- 3 Consumer Discretionary Stocks Ready for a Comeback in 2025
- How to Know if a Stock Pays Dividends and When They Are Paid Out
- Top 3 Robotics and Automation Stocks for the Next AI Boom
Receive News & Ratings for Gyre Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gyre Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
